Effect of Alogliptin/Pioglitazone on the Preservation of Long-term Beta-cell Function
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
All subjects will be randomized as Alo/Pio combo group (intervention) or Glim/Met combo group
(control) after intensive COAD treatment based on identical protocol.
- All subject will be managed with once daily, fixed dose, single tablet treatment based
on the study protocol, and followed-up for 104 weeks.
- Any group of subjects who fail to reach glycemic target with single tablet treatment,
subject will be treated with rescue medication and stopped regular observation.
Phase:
Phase 4
Details
Lead Sponsor:
Kyunghee University Medical Center
Collaborators:
Ajou University School of Medicine Bucheon St. Mary's Hospital Inha University Hospital Kangbuk Samsung Hospital Korea University Guro Hospital Kyung Hee University Hospital at Gangdong Seoul Medical Center Takeda